Related references
Note: Only part of the references are listed.Clinicopathological and functional implications of the inhibitor of apoptosis proteins survivin and XIAP in esophageal cancer
Levent Dizdar et al.
ONCOLOGY LETTERS (2018)
Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia
Levent Dizdar et al.
ONCOTARGET (2017)
Survivin and gynaecological tumours
Dusan Brany et al.
PATHOLOGY RESEARCH AND PRACTICE (2017)
High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth
Marieke A. de Graaff et al.
TRANSLATIONAL ONCOLOGY (2017)
Survivin and XIAP expression in distinct tumor compartments of surgically resected gastric cancer: XIAP as a prognostic marker in diffuse and mixed type adenocarcinomas
Levent Dizdar et al.
ONCOLOGY LETTERS (2017)
Survivin and XIAP - two potential biological targets in follicular thyroid carcinoma
Thomas A. Werner et al.
SCIENTIFIC REPORTS (2017)
Targeting survivin for therapeutic discovery: past, present, and future promises
Robert C. Peery et al.
DRUG DISCOVERY TODAY (2017)
Prognostic factors and outcome of Liposarcoma patients: a retrospective evaluation over 15 years
Carolin Knebel et al.
BMC CANCER (2017)
Phase III Soft Tissue Sarcoma Trials: Success or Failure?
Alexander T. J. Lee et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2017)
Peritoneal sarcomatosis: site of origin for the establishment of an in vitro and in vivo cell line model to study therapeutic resistance in dedifferentiated liposarcoma
Sabrina Mersch et al.
TUMOR BIOLOGY (2016)
Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma
Thomas A. Werner et al.
BRITISH JOURNAL OF CANCER (2016)
Small Molecule Survivin Inhibitor YM155 Displays Potent Activity Against Human Osteosarcoma Cells
Shufeng Zhang et al.
CANCER INVESTIGATION (2016)
Liposarcoma Multimodality Management and Future Targeted Therapies
Aimee M. Crago et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2016)
Silencing of Survivin Using YM155 Inhibits Invasion and Suppresses Proliferation in Glioma Cells
Hua Guo et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2015)
YM155 reverses rapamycin resistance in renal cancer by decreasing survivin
Hidekazu Koike et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Uterine Leiomyosarcoma Management, Outcome, and Associated Molecular Biomarkers: A Single Institution's Experience
Kristelle Lusby et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
Oktay Tacar et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2013)
Role of survivin as prognostic and clinicopathological marker in gastric cancer: a meta-analysis
Andreas Krieg et al.
MOLECULAR BIOLOGY REPORTS (2013)
Survivin Signaling in Clinical Oncology: A Multifaceted Dragon
Jagat R. Kanwar et al.
MEDICINAL RESEARCH REVIEWS (2013)
BIRC5 Expression Is a Poor Prognostic Marker in Ewing Sarcoma
Pooja Hingorani et al.
PEDIATRIC BLOOD & CANCER (2013)
Prognostic and Clinicopathological Significance of Survivin in Colorectal Cancer: A Meta-Analysis
Andreas Krieg et al.
PLOS ONE (2013)
Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival
A. Italiano et al.
ANNALS OF ONCOLOGY (2012)
Sepantronium Bromide (YM155) induces disruption of the ILF3/p54nrb complex, which is required for survivin expression
Tomohiro Yamauchi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Survivin Is a Viable Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors
Markus P. Ghadimi et al.
CLINICAL CANCER RESEARCH (2012)
Copy Number Losses Define Subgroups of Dedifferentiated Liposarcoma with Poor Prognosis and Genomic Instability
Aimee M. Crago et al.
CLINICAL CANCER RESEARCH (2012)
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
Jordi Barretina et al.
NATURE GENETICS (2010)
Multifocality in Retroperitoneal Sarcoma A Prognostic Factor Critical to Surgical Decision-Making
Daniel A. Anaja et al.
ANNALS OF SURGERY (2009)
LS14 cells - A model for chemoresistance in liposarcoma
Elizabeth W. LaPensee et al.
CANCER BIOLOGY & THERAPY (2007)
Expression of survivin in renal cell carcinomas: Association with pathologic features and clinical outcome
Seok-Soo Byun et al.
UROLOGY (2007)
Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk
Kimberly Moore Dalal et al.
ANNALS OF SURGERY (2006)
Atypical lipomatous tumor/well-differentiated liposarcoma of the extremity and trunk wall: Importance of histological subtype with treatment recommendations
DA Kooby et al.
ANNALS OF SURGICAL ONCOLOGY (2004)
Survivin is an independent prognostic marker for risk stratification of breast cancer patients
PN Span et al.
CLINICAL CHEMISTRY (2004)
Demystified ... Tissue microarray technology
J Packeisen et al.
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY (2003)
Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas
C Mahotka et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Share Paper
